Buparlisib (BKM120)

Catalog No.S2247 Synonyms: NVP-BKM120

For research use only.

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

Buparlisib (BKM120) Chemical Structure

CAS No. 944396-07-0

Selleck's Buparlisib (BKM120) has been cited by 230 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
Click to View More Targets
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
glioma cell lines MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfWOnlTPzKq NEnneHlKSzVyPUGtNu69VQ>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB4NUC4NEc,OjJyNkWwPFA9N2F-
U87 NYLPW2FxSXCxcITvd4l{KEG|c3H5 M{L3ZVLPxE1? NXzYdph4PzKq NYe1VmticW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM> M3vmSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{ME[1NFgxLz5{MkC2OVA5ODxxYU6=
SNU-601 M4jhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3Nog> NHK1cotFVVOR MmL0TWM2OD1yLkixOuKyOC5yNkROwG0> NFPsWlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-1 M1yyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXkTWZDPzKq NGDBfphFVVOR MlzyTWM2OD1zLkC4NuKyOC5yMklOwG0> NXnkdFdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-668 M3jtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHRO|Jp Mkm4SG1UVw>? MYHJR|UxRTFwNUe5xtExNjB5NN88US=> MmiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
AGS Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDydlM4Omh? NWHC[28{TE2VTx?= Mnn2TWM2OD1zLkexOOKyOC5zMUhOwG0> NIPPV|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-216 NUfHdYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrSVJM4Omh? M2PGOGROW09? NFzYRldKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? NHO3OJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHMO|Jp NFXPNJVFVVOR M3rpXmlEPTB;MT6zOVHDuTBwMEmx{txO M4PmWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-638 M1W1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXFO|Jp MWPEUXNQ M2ftOWlEPTB;Mj6yPFLDuTBwMEWz{txO Ml\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLEO|Jp M{[5bWROW09? NV;BfVVOUUN3ME2xMlU4O8LzMD6wNFHPxE1? MoTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-484 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jPclczcA>? Moi1SG1UVw>? MXfJR|UxRTFwN{K4xtExNjB2Nd88US=> Ml;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-620 NEjkU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[3NlE4Omh? NWjlb25DTE2VTx?= M2fqdmlEPTB;Mj65N|nDuTBwMECx{txO NGPxWVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-719 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLEWGNKPzKq M1e2VWROW09? M1;hW2lEPTB;Mz6wN|fDuTBwMEOy{txO MoS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
MM cell lines M1j4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxNO69VQ>? MUOyOIg> Mny2SG1UVw>? MWLJR|UxKH[jcnnld{BidW:wZzDkbYZn\XKnboSgZ4VtdCCuaX7ld{BqdiC2aX3lJIFv\CCmb4PlJIRmeGWwZHXuZ4U> NI[zUJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKwO|Q5PSd-MkKyNFc1QDV:L3G+
ARP-1 NUfoZ3R[SXCxcITvd4l{KEG|c3H5 Mm\LNVDPxE1? MoXYNlRp NHHWXFdFVVOR NVTObJZicW6mdXPld{BOVSClZXzsJIFxd3C2b4Ppd{B1cHKxdXfoJINie3Cjc3WgZYN1cX[jdHnvci=> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyN{S4OUc,OjJ{MEe0PFU9N2F-
colon cancer cell lines NGn6cYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr5NE0yOM7:TR?= NH71eWw4Omh? NVnvWZlUTE2VTx?= MmTtTWM2OD1zzszN MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2M{i1O{c,OjJ3NEO4OVc9N2F-
gastric cancer cell lines NEP2coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3FVlAxNTFyzszN MYi3Nog> MnjhSG1UVw>? NHPQ[XlKSzVyPUKtOe69VQ>? NV\YTItxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFM5PTdpPkKyOVQ{QDV5PD;hQi=>
HCT-116/HT-29/MKN-45 Mln0RZBweHSxc3nzJGF{e2G7 M1PLSFLPxE1? MnrrOFhp M1LBT5NpcW[2IHnuJGczKHCqYYPl M{\HZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N|g2PzxxYU6=
HT-29 and HCT-116 NF\1V5NE[XOyYYPlJIF{e2G7 MkO2Oe69VQ>? MmnrNlRp M3[xUYlv\HWlZYOgZ4F{eGG|ZTDhZ5Rqfmm2eR?= MoXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEO4OVcoRjJ{NUSzPFU4RC:jPh?=
PIK3CA-mutant MCF7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLpS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? M4LmRVczcA>? MUTHTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? M3npNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkWzPVY4Lz5{Mk[1N|k3PzxxYU6=
PIK3CA-mutant MCF7 MlzMT4lv[XOnIFHzd4F6 NEDDWFlKSzVyPUGxOOKyO26P MoLJO|Jp MmnLTWM2OD1zMUVCtVNvVSCrbjDy[YR2[2mwZzDBb5QheGixc4Doc5J6dGG2aX;uJIxmfmWucx?= Mli3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlcoRjJ{NkWzPVY4RC:jPh?=
MCF7-myr-Akt Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXrS2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? M{nUelczcA>? M2HXb2dKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P MoDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlcoRjJ{NkWzPVY4RC:jPh?=
Y1 cell line MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6wMlHPxE1xMd88US=> MWmyOIg> MoTZSG1UVw>? NUnteVRycW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= NYHnTYNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PVI6ODRpPkKyOlkzQTB2PD;hQi=>
human NSCLC M2G5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq3UHVGOC53LUNOwG0> NWrTOGtuPzKq MoDRTWM2OD1zzszN MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd6MUO5N{c,OjJ5OEGzPVM9N2F-
human NSCLC NGDPRZhMcW6jc3WgRZN{[Xl? NVvU[|ZQOc7:TR?= M3u2V|I1cA>? MofhbY5pcWKrdIOgeIhmKEGtdD;tWG9TKHOrZ37hcIlv\yCyYYToe4F6KGG2IEPoJIFnfGW{IITy[YF1dWWwdB?= MmXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEGzPVMoRjJ{N{ixN|k{RC:jPh?=
JVM2 M{DOd2N6fG:2b4jpZ4l1gSCjc4PhfS=> Ml3GNE4zNTJyzszN M1LWTVczcA>? NYPrTIxNTE2VTx?= MoHUTWM2OD1yLkpOwG0> M{HoVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
EHEB NYDLTmt1S3m2b4TvfIlkcXS7IHHzd4F6 M3vjc|AvOi1{MN88US=> M4\VR|czcA>? MmPKSG1UVw>? MXzJR|UxRTBwN988US=> MojIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N|koRjJ|MkO4OlM6RC:jPh?=
MEC2 NH\pWJFEgXSxdH;4bYNqfHliYYPzZZk> NUj6Z25VOC5{LUKw{txO MUG3Nog> NEDPZoRFVVOR NF3zW2FKSzVyPUCuO:69VQ>? MkX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N|koRjJ|MkO4OlM6RC:jPh?=
primary B-CLL lymphocytes NGW1fXZCeG:ydH;zbZMhSXO|YYm= M3TIZWlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? NFHhb44zPGh? M2nmUWROW09? MXHJR|Ux97zeM988UUBnd3JiYXzsJJBifGmnboTz MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ|OE[zPUc,OjN{M{i2N|k9N2F-
primary B-CLL lymphocytes NYrwdHFpU2mwYYPlJGF{e2G7 NYixNYVFUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= M3izU|I1cA>? Mo\XbY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= NUnvZmJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN|g3OzlpPkKzNlM5PjN7PD;hQi=>
SK-HEP1 NU[xUG1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPRNVIyNTJyzszN MnPYO|Jp MUjEUXNQ MUjJR|Ux97zeMd88US=> MnTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{mxN|YoRjJ|NEe5NVM3RC:jPh?=
786-0 M1SzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3Fd4RzOS1{MN88US=> NFXRXYc4Omh? NYfJPGF[TE2VTx?= NIm5fohKSzVy78{cNe69VQ>? M3LnWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEe5NVM3Lz5{M{S3PVE{PjxxYU6=
human HCC cell lines NFnKOWFE\WyuII\pZYJqdGm2eTDhd5NigQ>? MXOwMlAxPS1zzszN NHyxW2I1QGh? NVyzeYh{UUN3ME2x{txO M2G2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEi5PVk6Lz5{M{S4PVk6QTxxYU6=
Huh7 MX;LbY5ie2ViQYPzZZk> MmfuNe69VQ>? NHTUXlI1QGh? Mn25d4lodmoxrJHjZY51dHlicnXkeYNmeyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0 MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEm5PVkoRjJ|NEi5PVk6RC:jPh?=
human NSCLC cell lines NUHE[WRPSXCxcITvd4l{KEG|c3H5 M3;jbFAvOTJ3LUVOwG0> NH;LfG8zPGh? NILNVW5FVVOR MV\JR|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?= M2LLT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NU[yOFczLz5{M{W2NlQ4OjxxYU6=
Primary CLL cells MlnXRZBweHSxc3nzJGF{e2G7 MY[xMVEx|ryP NYHWO3RyPDiq NXTFPWltcW6mdXPld{BieG:ydH;zbZMhcW5iQ1zMJINmdGy|IHnu[IVx\W6mZX70JI9nKHC{b3fuc5N1cWNibXHyb4Vzew>? NVzaWlg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVA5ODdpPkKzPFUxQDB5PD;hQi=>
Primary CLL cells MmTKT4lv[XOnIFHzd4F6 Mn7rNu69VQ>? MYSzNI1qdg>? MkDO[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? NHTzN489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
Primary CLL cells NYLjZpRyS3m2b4TvfIlkKEG|c3H5 NIn0UZAz|ryP Mnr0NlRp MYnpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 NHrFcpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
LC-1/SQSF MljISpVv[3Srb36gRZN{[Xl? MnnwN:69VQ>? NGHuUG8zPGh? NXzRWIY6TE2VTx?= M33UV4Rm[3KnYYPlJG5TTjJicILveIVqdiCuZY\lcC=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl6MEC5N{c,OjN7OECwPVM9N2F-
BCR-ABL M3S0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vpelAvOjVvMUFOwG0> NXjZeol6PGR? NF;Gd3F{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w NYf6RYNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQ3OTJpPkK0NlQ1PjF{PD;hQi=>
T-ALL MoPTRZBweHSxc3nzJGF{e2G7 M4rpWYJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= MVqyOEBweiB2OHi= NEDCVJVFVVOR NWq2SHB5[W[oZXP0d{B1cGViUFmzT{Bx[XSqd3H5JIlvKFRvQVzMJINmdGxibHnu[ZM> Moq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MUC3N|YoRjJ2M{GwO|M3RC:jPh?=
H1975 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjzNE4{NTlwNt88US=> Mn3aO|Jp M4Xic2ROW09? MXvJR|UxRTFwM{i1{txO MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN|N{i0Okc,OjR|M{e4OFY9N2F-
H1975 M1SzSmFxd3C2b4Ppd{BCe3OjeR?= NEC1b5Iz|ryP NID0V4MzPGh? NXL5UYRNTE2VTx?= MWPpcoNz\WG|ZYOgZZBweHSxc3nzJJJifGVic3nncolncWOjboTsfS=> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN|N{i0Okc,OjR|M{e4OFY9N2F-
BON MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\O[Zg4OS13zszN NGfObW84Omh? NY\CZpRp\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MlLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NEO1NlMoRjJ2NESzOVI{RC:jPh?=
BON M3fQTmFxd3C2b4Ppd{BCe3OjeR?= MkXzNU02|ryP NYrPd4dQOjSq MXTpcoNz\WG|ZYOgZZBweHSxc3nz MlqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NEO1NlMoRjJ2NESzOVI{RC:jPh?=
GBM MkT2RZBweHSxc3nzJGF{e2G7 M33GT|LPxE1? NELDSHc1QGh? NXfvW45pTE2VTx?= NXfSe5hRcW6mdXPl[EBpcWeqZYKgcIV3\Wy|IH;mJIFxd3C2b4Ppd{wh[W6mIHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gQ>? NWSzV3NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFA1QTJpPkK0OVAxPDl{PD;hQi=>
FaDu NEPVRYxHfW6ldHnvckBCe3OjeR?= MWe1JO69VQ>? NXLxO45FOjRiaB?= M3\FWWROW09? MoS4VoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= NGHWSVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N|EyPDd:L3G+
EMT6 M1zTbGZ2dmO2aX;uJGF{e2G7 NY\0XYdlPSEQvF2= Mnv3NlQhcA>? NVrs[IVHTE2VTx?= M2nZb3Jm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
HCT116 MofWSpVv[3Srb36gRZN{[Xl? MXW1JO69VQ>? MnSyNlQhcA>? M3O0fmROW09? NW\1c2N{WmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NGjwVpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N|EyPDd:L3G+
U87 MYHGeY5kfGmxbjDBd5NigQ>? MUi1JO69VQ>? NUHhSYllOjRiaB?= MXHEUXNQ NIfVeHZT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NWq2NGk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N|EyPDdpPkK0OlMyOTR5PD;hQi=>
Saos-2 NEHkc5ZHfW6ldHnvckBCe3OjeR?= MVy1NEDPxE1? NGSwc3o1QCCq M1vBb2lvcGmkaYTzJINmdGxiaX72ZZNqd25? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
MG-63 MXXGeY5kfGmxbjDBd5NigQ>? NYPiVYxoPTBizszN NHP4NWU1QCCq NIj4TIlKdmirYnn0d{Bk\WyuIHnueoF{cW:w M3O5d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO|Y3ODxxYU6=
SJSA-1 NV\GN2FzTnWwY4Tpc44hSXO|YYm= NFnMRZc2OCEQvF2= MWC0PEBp NInJPVdKdmirYnn0d{Bk\WyuIHnueoF{cW:w NFzve|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO|Y3OCd-MkS3Nlc3PjB:L3G+
Saos-2 M{WzTGZ2dmO2aX;uJGF{e2G7 MYW1NEDPxE1? MmnEOFghcA>? Mmn1TY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> NETiS3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63 MV3GeY5kfGmxbjDBd5NigQ>? M3ntclUxKM7:TR?= MY[0PEBp MW\Jcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u M1rPZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO|Y3ODxxYU6=
SJSA-1 NFTSV25HfW6ldHnvckBCe3OjeR?= MUG1NEDPxE1? MlftOFghcA>? NIO5cldKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NWCyPHgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O|I4PjZyPD;hQi=>
Saos-2 NVnjS2ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3vbmE{PTBizszN MnHPOFghcA>? NFPNUI9KdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Mn6yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
MG-63 NFXLdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHGd2RGPTBizszN MlH4OFghcA>? M2CxXGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NHL2cGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1 M{LRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOSIQ2OCEQvF2= Mk\rOFghcA>? NYm3SVhuUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
LN18 NHLE[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCyNEDPxE1? MlrPO|IhcA>? M1jCOmROW09? Mm[0TWM2ODx3IN88US=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO|Q9N2F-
LN229 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uzZ|IxKM7:TR?= NWfIemFSPzJiaB?= NIW5XHBFVVOR NFXzVoJKSzVyPEWg{txO NYDaU21bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O|QyODd2PD;hQi=>
LNZ308 NHXHZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKyNEDPxE1? MmXYO|IhcA>? NH73bYhFVVOR NVzNVnhtUUN3MEy1JO69VQ>? NFHJZYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
T98G MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD4NlAh|ryP NX7UfJVIPzJiaB?= NGTTdmVFVVOR NIjPUGtKSzVyPEWg{txO M{jCflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
U87 NYLkWZppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDNR4gzOCEQvF2= M3rP[|czKGh? NF;QfFJFVVOR NYm0b41iUUN3MEy1JO69VQ>? NEPtfHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LN18 M3r5UWZ2dmO2aX;uJGF{e2G7 M2jBfFUh|ryP NUXhSlJTOjRiaB?= MkHISG1UVw>? NHXpcoVKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW M{G3b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
LNZ308 M1;FZ2Z2dmO2aX;uJGF{e2G7 MUi1JO69VQ>? M3fQNlI1KGh? MWrEUXNQ MXXJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV MlLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO|QoRjJ2N{SxNFc1RC:jPh?=
MDA-MB-175 NVnsfIx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmxJO69VQ>? NHXVXJM2KGR? MWrEUXNQ NITDWlVKSzVyPEGg{txO Mn3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
MDA-MB-134 NFHB[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;0NUDPxE1? NVrGSoY5PSCm Ml\rSG1UVw>? MVfJR|UxRDFizszN Ml7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
HCC1500 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KxbFEh|ryP NXjESVd1PSCm MmLUSG1UVw>? M3\YbGlEPTB:MTFOwG0> M2CzSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
EFM-19 NIfRdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor5NUDPxE1? MXy1JIQ> Ml7LSG1UVw>? NXGxUm51UUN3MEyxJO69VQ>? M2nYXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
ZR-75-30 NH3vV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxJO69VQ>? NXvpZ5BnPSCm NGC1UGNFVVOR NYfIbZA5UUN3MEyxJO69VQ>? M2\UeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
MDA-MB-361 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj4NUDPxE1? MWq1JIQ> M33rSmROW09? MVfJR|UxRDFizszN Mn6yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
T-47D NX7sc4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7PdHcyKM7:TR?= NUHUcHNFPSCm MnnTSG1UVw>? NYPHclB5UUN3MEyxJO69VQ>? M4LublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
SK-BR-3 NFz3XVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmxJO69VQ>? MknSOUBl MlTHSG1UVw>? MmC0TWM2ODxzIN88US=> M1ryb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
UACC-732 NF;3NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK1O5luOSEQvF2= M1jUN|Uh\A>? NE\ZSYlFVVOR M3nLdmlEPTB:MTFOwG0> NGHucVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
BT-474 NXLuOG5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nSdFEh|ryP NUjZfpNwPSCm M2qyNmROW09? NWXNVWFwUUN3MEyxJO69VQ>? NHXkSXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
HCC202 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqxJO69VQ>? M3rZVVUh\A>? MVLEUXNQ NH63T3FKSzVyPEGg{txO NGXDR4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
MCF7 Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGwNUDPxE1? NGO1ZoE2KGR? MoWySG1UVw>? NVvBenZDUUN3MEyxJO69VQ>? MlHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
MDA-MB-415 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUixJO69VQ>? NF;hdGU2KGR? MYfEUXNQ MorCTWM2ODxzIN88US=> M{\UUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
MDA-MB-453 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTufI8yKM7:TR?= M3jIUFUh\A>? M1H3VGROW09? MUfJR|UxRDFizszN NXfX[oU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
ZR-75-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmxJO69VQ>? MXO1JIQ> M3zTeWROW09? MWfJR|UxRDFizszN MknCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
HCC38 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\oOVEh|ryP MYe1JIQ> NFe2[JBFVVOR NFjoZmxKSzVyPEGg{txO NWm0Vm1HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1419 NWe4UYNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHl[WoyKM7:TR?= NInJeII2KGR? NFjGOIVFVVOR MU\JR|UxRDFizszN M13HNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
UACC-812 M4SyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHezN44yKM7:TR?= NXXzSmpiPSCm NX62[FFYTE2VTx?= MoXUTWM2ODxzIN88US=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1187 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33jRlEh|ryP MoGyOUBl M{LjZmROW09? NFKx[IZKSzVyPEGg{txO NVW4UppbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
KPL-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrzNUDPxE1? NVHpdWRSPSCm NYXBfm1iTE2VTx?= M4rHZ2lEPTB:MTFOwG0> NYTJcIVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
SUM-225 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuyTXp7OSEQvF2= NXf1[ItKPSCm NVP3Z4JKTE2VTx?= MoTRTWM2ODxzIN88US=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
EFM-192A Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofaNUDPxE1? MmjEOUBl M{D1SGROW09? MUHJR|UxRDFizszN NVLwU|RrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
JIMT-1 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLTU3YyKM7:TR?= M{fFXVUh\A>? M1r1UGROW09? Mn\nTWM2ODxzIN88US=> MlvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
HCC1143 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnONUDPxE1? NV;sUVhwPSCm NGTzc5ZFVVOR MV3JR|UxRDFizszN M37FVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
HCC2218 NETzUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxJO69VQ>? M2jLclUh\A>? NWDKcY1mTE2VTx?= M3;5VWlEPTB:MTFOwG0> NXHuTlQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-468 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjYTGhyOSEQvF2= MUC1JIQ> MkHESG1UVw>? NX\1VGk6UUN3MEyxJO69VQ>? MlLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
BT-20 NFfVfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrxeW5vOSEQvF2= MlLHOUBl Mo\jSG1UVw>? M4jlZmlEPTB:MTFOwG0> M1OzVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
MDA-MB-435 M1XZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xJO69VQ>? MWe1JIQ> M{WwcWROW09? NVzufFlsUUN3MEyxJO69VQ>? NUPZRYZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-549 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyxJO69VQ>? MXG1JIQ> NIrqXGpFVVOR NIn2Um9KSzVyPEGg{txO MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1806 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\yNUDPxE1? M2LnZlUh\A>? Mn3OSG1UVw>? Ml7ZTWM2ODxzIN88US=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1937 NX7TXnl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P1[VEh|ryP MUG1JIQ> M2DzXmROW09? M3zvZmlEPTB:MTFOwG0> NWLPcIdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
Hs578T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXENUDPxE1? MUC1JIQ> MX3EUXNQ MWjJR|UxRDFizszN M4jaVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
MCF7 Mk\JR5l1d3SxeHnjJGF{e2G7 M4LxVFczKGh? NV7BS|c3TE2VTx?= NWLPcZRZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
DU145 NWjoU|hbS3m2b4TvfIlkKEG|c3H5 NYrLd5FbPzJiaB?= M3PKNGROW09? MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? M4PiTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
A2780 NFT5XoZEgXSxdH;4bYMhSXO|YYm= M2DVW|czKGh? NGTMXWlFVVOR MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N|Uh|ryP NYrNbIRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
U87MG NXXJ[ZRKS3m2b4TvfIlkKEG|c3H5 M4P4[|czKGh? NI[xfo5FVVOR MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2PVgh|ryP NFvWUYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780 NWHucGwyTnWwY4Tpc44hSXO|YYm= NVqzcWRJOSCq MkiySG1UVw>? MUnJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>? MnXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
DU145 NH2w[GRHfW6ldHnvckBCe3OjeR?= M33MS|EhcA>? MWHEUXNQ MYTJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gSHUyPDViY3XscJMhcGG{Yn;ybY5oKEyNQkGgcZV1[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEezJO69VQ>? M37OcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
A2780 Mm\FSpVv[3Srb36gRZN{[Xl? MVixJIg> NX\3TnRHTE2VTx?= M3O4VmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP MlzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
MCF7 M2LBXGZ2dmO2aX;uJGF{e2G7 M3fuVVEhcA>? NULXcHI6TE2VTx?= MkTzTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO NXrEXHRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
U87MG MYHGeY5kfGmxbjDBd5NigQ>? NUHpZ2hDOSCq NUjKOYhFTE2VTx?= M2T5fGlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1? NEnnWo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\NNlQ4OiCq M3:yWGROW09? NX35b3hTTUN3ME2wMlUzKM7:TR?= NYjtZpN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
Huh7 MmSwSpVv[3Srb36gRZN{[Xl? MUGxJO69VQ>? MmDuNUBp MmPsSG1UVw>? NWe5cY1RUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S= MmGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMES0NFMoRjJ3MEC0OFA{RC:jPh?=
BNL MkXSSpVv[3Srb36gRZN{[Xl? MnXzNUDPxE1? NX23U3hoOSCq M{fneGROW09? NV7BNlhpUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4 NHXYSGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOFQxOyd-MkWwNFQ1ODN:L3G+
BON-1 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy1NFAhdk1? NHnTVHIyOCCm MlrwSG1UVw>? M33Qe2lvcGmkaYTzJINmdGxiZ4Lve5Rp NUK2bWtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
BON-1 NHfZdIdHfW6ldHnvckBCe3OjeR?= MknLOVAxKG6P M4L1OFQhcA>? Ml22SG1UVw>? MlLlTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= NXG0XVhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
QGP-1 NILnb2pHfW6ldHnvckBCe3OjeR?= NYPOWYVWPTByIH7N MnrROEBp NIXEcZdFVVOR NUfsSJJnUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> MnrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
HCT-15 NWe2dmc1SXCxdH;zbZMhSXO|YYm= MXexNEDPxE1? NUK5Xpg4PDhiaB?= MULEUXNQ NVzxS5ZsUW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVE2KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= NYTpXYNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
HCT-116 MnH1RZBwfG:|aYOgRZN{[Xl? NHL2V5cyOCEQvF2= NYnGOo9HPDhiaB?= MYfEUXNQ MkiyTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
NCI-H460 NHXKXY1CeG:2b4Ppd{BCe3OjeR?= MWGxNEDPxE1? NFzZPYQ1QCCq NYLQNopVTE2VTx?= MVjJcoR2[2W|IHHwc5B1d3OrczDpckBPS0lvSES2NEBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NIXWNos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
SKOV-3 Mo\yRZBwfG:|aYOgRZN{[Xl? NYqzOWcyOTBizszN MVO0PEBp NHLtfmZFVVOR MXzJcoR2[2W|IHHwc5B1d3OrczDpckBUU0:YLUOgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NUjNW|F4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
BSY-1 M4G1b2Fxd3Sxc3nzJGF{e2G7 NHS0enIyOCEQvF2= MWO0PEBp M{fhbGROW09? NIr2ToZKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w Mn\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
MKN-1 M{PjVGFxd3Sxc3nzJGF{e2G7 M3TYeVExKM7:TR?= NYnSe2FPPDhiaB?= NW\VRpVOTE2VTx?= NGHOPJNKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCPS16tNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NGnPXWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
NCI-H522 MULBdI91d3OrczDBd5NigQ>? NG\wRW8yOCEQvF2= NEXMdJc1QCCq NEWwfGdFVVOR MkfzTY5lfWOnczDhdI9xfG:|aYO= MljLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
OVCAR-3 M2rzZmFxd3Sxc3nzJGF{e2G7 MXKxNEDPxE1? MkXvOFghcA>? M2LYT2ROW09? NV3DTVZRUW6mdXPld{BieG:ydH;zbZM> NGe3OXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
HBC-5 NIHjd2FCeG:2b4Ppd{BCe3OjeR?= MUmxNEDPxE1? MVi0PEBp NFXoNWpFVVOR NFK3TWFKdmS3Y3XzJIFxd3C2b4Ppdy=> M3rMSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
RXF-631L M{fYOGFxd3Sxc3nzJGF{e2G7 NWrKNJFiOTBizszN M17lSVQ5KGh? NIT2[FhFVVOR M2PzcWlv\HWlZYOgZZBweHSxc3nz NV\rUW5xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
MKN-45 NE\WNVFCeG:2b4Ppd{BCe3OjeR?= NEXxW40yOCEQvF2= NG\lRXk1QCCq M{O0W2ROW09? Mn7nTY5lfWOnczDhdI9xfG:|aYO= M2m5flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
LNCaP NX;tVVBJTnWwY4Tpc44hSXO|YYm= Ml20NUDPxE1? MUnTeZBxemW|c3XzJJAuSUuWIHzleoVtew>? M1LPd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wO|k6Lz5{NUO2NFc6QTxxYU6=
LNCaP95 M1TPbWZ2dmO2aX;uJGF{e2G7 MnzXNUDPxE1? NF;OS4VUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MEe5PUc,OjV|NkC3PVk9N2F-
A549 MWfGeY5kfGmxbjDBd5NigQ>? NYjkU21qPTByIH7N MX60PEBp MULEUXNQ NWDMdnFyUW6qaXLpeJMhSWu2IHHjeIl3[XSrb36= M4P6NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO|I6QTxxYU6=
A549 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\ZZWIyKM7:TR?= Mkf3O|IhcA>? NG\xVZNFVVOR MojBTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl|N{K5PUc,OjV7M{eyPVk9N2F-
H522 M1e3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxJO69VQ>? MoqwO|IhcA>? NVPLXYFETE2VTx?= NGO4dI9KdmirYnn0d{Bk\WyuIHfyc5d1cA>? NUnXO5hFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N|czQTlpPkK1PVM4Ojl7PD;hQi=>
SKMES-1 Mmq0R5l1d3SxeHnjJGF{e2G7 NXzOS49bOSEQvF2= NHzLeWo4OiCq MonpTY5lfWOnczDj[YxtKGSnYYTo NV3XSIZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
H596 NGjqUGlHfW6ldHnvckBCe3OjeR?= M1nUZ|Eh|ryP M3e2bmlueGGrcoOgZ4VtdCCvaXfyZZRqd25? NHSwdnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCxN|MyQCd-Mk[wNVM{OTh:L3G+
HCC2450 NEH3blZHfW6ldHnvckBCe3OjeR?= M1ywWlEh|ryP MmrDTY1x[Wm{czDj[YxtKGmwdnHzbY9v NX\WRYZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
HCT116 NGjvUItCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXK3NkBpenN? NHzWPFhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE41QCEQvF2u NE\XUpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
MCF7 MlLORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NH3KOXI4OiCqcoO= NWr3V5JsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxJO69VS5? NUT1WIxvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O|Y2QTB7PD;hQi=>
U87MG MXnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M1XQbFczKGi{cx?= NIC2bVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxMlY1KM7:TT6= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
A549 M{fPNmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Ml3iO|IhcHK| NHjvNFRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuNFch|ryPLh?= NFu5Vnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
HeLa Ml;KRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWK3NkBpenN? NEPiW4xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IESuN|Qh|ryPLh?= NWnVWGJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O|Y2QTB7PD;hQi=>
HCT116 MWjGeY5kfGmxbjDhd5NigQ>? M13obVExKHWP MkPqNUBpeg>? MnLuTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhSWu2IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm|aYO= NH\FdFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
A2058 melanoma NH71XVhE\WyuIHP5Z4xmKGG|c3H5 M3i3UFUhfU1? Moj0NlQhcHK| NHTWRVNE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCOjB3ODDt[Yxidm:vYTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiU4XiS|EheGijc3WgZZQhPSC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m| M4\DRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK5OVkzLz5{OEiyPVU6OjxxYU6=
A2058 melanoma NFvCfVhE\WyuIHP5Z4xmKGG|c3H5 M4jjNFUhfU1? MWWyOEBpenN? MVTD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDBNlA2QCCvZXzhco9u[SClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDC1JJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> M2\SUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK5OVkzLz5{OEiyPVU6OjxxYU6=
SKOV3 NEL4XoNE\WyuIHP5Z4xmKGG|c3H5 NHLaUpkzKHWP Mki2NlQhcHK| MV3D[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDTT29XOyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDCyJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> MoS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
SKOV3 MkTJR4VtdCCleXPs[UBie3OjeR?= MVmyJJVO MnW1NlQhcHK| MX;D[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDTT29XOyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhW3WkR{GgdIhie2ViYYSgNkB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{ NVrUb3NQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
MDA-MB-231 MXTDfZRwfG:6aXPpeJkh[XO|YYm= NUXGNHRLPzJiaILz Mn7oR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMT64PEDPxE1w NVzuNWdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNFc1OjlpPkK5NVA4PDJ7PD;hQi=>
PC3 NH7PSGhEgXSxdH;4bYNqfHliYYPzZZk> M1HIeFczKGi{cx?= NWLBTHFES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA2NjN2IN88UU4> M{LNfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO|QzQTxxYU6=
T47D MVTDfZRwfG:6aXPpeJkh[XO|YYm= M2fhWVczKGi{cx?= MnfPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gOk46OiEQvF2u M2SyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO|QzQTxxYU6=
MCF7 NGLOOI5EgXSxdH;4bYNqfHliYYPzZZk> MkfuO|IhcHK| M3i2UGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEyNjB3IN88UU4> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
TC32 NVrHOYdKeUiWUzDhd5NigQ>? MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? NV3sdpV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NGXLXZByUFSVIHHzd4F6 MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY NH64cpdyUFSVIHHzd4F6 MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? M4THPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 NX7hRnRbeUiWUzDhd5NigQ>? MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NVO3fIt4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 NEPpfIJyUFSVIHHzd4F6 NHvvNFVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= NUjIN4wxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD M4nqe5FJXFNiYYPzZZk> MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH MWfxTHRUKGG|c3H5 MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 NWnOVnNYeUiWUzDhd5NigQ>? NV;aV5NueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) NGfWPFByUFSVIHHzd4F6 MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NE\CXZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MYLxTHRUKGG|c3H5 Ml62dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NUXu[VR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M3n6R5FJXFNiYYPzZZk> NEjXV25yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NU\IUpVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M3zwNZFJXFNiYYPzZZk> MlzMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>? M3zBXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NHzSVmtyUFSVIHHzd4F6 M3HQ[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| NVXxcoMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MU\xTHRUKGG|c3H5 Mle4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 M1OxS5FJXFNiYYPzZZk> NEiwcmtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= M4HldFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MULxTHRUKGG|c3H5 NXG4fXJ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NVjCfGZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 NW\jPXg3eUiWUzDhd5NigQ>? M3vHSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM> Mn3BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS M2LERpFJXFNiYYPzZZk> M1vSOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 NGDvNZpyUFSVIHHzd4F6 M3r4ZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM> NG\YNpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MkfRdWhVWyCjc4PhfS=> NWHuSJlxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 Mn3xdWhVWyCjc4PhfS=> NGDsV21yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MnK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NX;3fWRmeUiWUzDhd5NigQ>? NF3QOmNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NVv4bHQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 Mor1dWhVWyCjc4PhfS=> M3\LZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MkfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NF;idmxyUFSVIHHzd4F6 MljUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| NVvs[XU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 NVL5[FhxeUiWUzDhd5NigQ>? MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NUXIfVhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NHXhbo5yUFSVIHHzd4F6 M32yTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? M17Jd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 MYXxTHRUKGG|c3H5 MmO0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> NW\CWXV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
insect MmrWSpVv[3Srb36gZZN{[Xl? M{K4VGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSHnzMZRi\2enZDDwPFVidHCqYT;wNVEx[WyyaHGgSVU1PUtibYX0ZY51KGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjBzMTFOwG0v NUDhbZpvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
insect MVnGeY5kfGmxbjDhd5NigQ>? M2XoTmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSHnzMZRi\2enZDDwPFVidHCqYT;wNVEx[WyyaHGgSVU1OktibYX0ZY51KGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjB{OTFOwG0v MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB|NE[wO{c,OzByM{S2NFc9N2F-
Sf21 NGfPVJhHfW6ldHnvckBie3OjeR?= M4iySFEhcHJ? MmTKTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHBzMUDk[Yx1[S:{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDwPFVidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBqdnOnY4SgZ4VtdHNidYPpcochWEmSMjDhd{B{fWK|dILheIUhdWWjc4Xy[YQh[W[2ZYKgNUBpeiCkeTDBcIV5[TZ|MzDUdoFk\XJvYnHz[YQh\my3b4Lld4NmdmOnIIDvcIFzNCCLQ{WwJF0hOC5zMkWg{txONg>? Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
MCF7 NH3YTZFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MoDxO|IhcHK| Mn\zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHjhdoJwemmwZzDQTWs{S0FiRUW0OWshdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlIxPiEQvF2u NYjPUIpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
Sf21 NH\4d2hHfW6ldHnvckBie3OjeR?= NXvyOY5WOSCqch?= NWDLTHk6UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtNWynbnf0bEBPNXSncn3pcoFtKEirc{[teIFo\2WmIICxNVBj\XSjL4LlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJJA5PWGucHjhJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yCSSWCyJIF{KHO3YoP0doF1\SCvZXHzeZJm\CCjZoTldkAyKGi{IHL5JGFt\XijNkOzJHRz[WOncj3iZZNm\CCobIXvdoV{[2WwY3WgdI9t[XKrLDDJR|UxKD1iMD6yN|Qh|ryPLh?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB|NE[wO{c,OzByM{S2NFc9N2F-
T47D MkX0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M16zTVczKGi{cx?= NGS0d5dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGS0O2Qh[2WubIOgbIFz[m:{aX7nJHBKO0uFQTDINVA1P1JibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ6NjFOwG0v NX[2cWRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
PC3 MoK5SpVv[3Srb36gZZN{[Xl? MVGyJIhzew>? MWXJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bu\WG|dYLl[EBi\nSncjCyJIhzeyCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlM3PSEQvF2u NV;5XI1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
HT-29 NF3U[IpE\WyuIHP5Z4xmKGG|c3H5 NEHtdnExNjFzMTD0c{A{KHWP MYeyOEBpenN? M3ziUGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFAvOTFzIITvJFMhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1enl? NWHI[JU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
A2058 M17CNGZ2dmO2aX;uJIF{e2G7 M3nIflEhcHJ? M4HvUGlvcGmkaYTpc44hd2ZiVF;SR|IhcW5iaIXtZY4hSTJyNUigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hWEuEL1HreEBxcG:|cHjvdplt[XSrb36gZZQhW2W{NEezJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMEBKSzVyIE2gNE41OTZizszNMi=> NG\DOo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO1PVAxOyd-M{CzOVkxODN:L3G+
A2058 NIDTbZNHfW6ldHnvckBie3OjeR?= MU[xJIhz NEP5Z45KdmirYnn0bY9vKG:oIGTPVmMyKGmwIHj1cYFvKEF{MEW4JINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFN4IIDoc5NxcG:{eXzheIlwdiCjdDDT[ZIzOzVxMkO2JIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMEBKSzVyIE2gNE42PTNizszNMi=> NXr4e3BvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOVkxODNpPkOwN|U6ODB|PD;hQi=>
Assay
Methods Test Index PMID
Western blot p-AKT (T308) / p-AKT (S473) / AKT ; p-FOXO3a (S253) / FOXO3a ; Nuclear NF-κB p65 / NF-κB p65 ; p-ERK / ERK / LC3 ; p-STAT3 / STAT3 / p-ERK / ERK / p-S6 ; p-MET / MET 27283525 28036259 26673665 27572309 29928341
Immunofluorescence FOXO3a 28036259
Growth inhibition assay Cell viability 26673665
In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol (from reference)

Kinase Assay:[1]
  • PI3K biochemical assay (ATP depletion assay):

    BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.

Cell Research:[1]
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
Animal Research:[1]
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

15mg/mL

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Recruiting Drug: Buparlisib & Paclitaxel Head and Neck Cancer Adlai Nortye Biopharma Co. Ltd. December 12 2020 Phase 3
NCT02614508 Terminated Drug: Buparlisib|Drug: Ibrutinib|Biological: Ofatumumab Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Drug: BKM120 Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Buparlisib (BKM120) | Buparlisib (BKM120) supplier | purchase Buparlisib (BKM120) | Buparlisib (BKM120) cost | Buparlisib (BKM120) manufacturer | order Buparlisib (BKM120) | Buparlisib (BKM120) distributor